|
|
A ruptured recurrent small bowel gastrointestinal stromal tumour causing hemoperitoneum |
Eric C.H. Lai1,3,Kam Man Chung2,Stephanie H.Y. Lau4,Wan Yee Lau1,*( ) |
1. Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong SAR, China 2. Dr. K.M. Chung’s Clinic, Rm 807, Hang Seng Tsimshatsui Building, 18 Carnarvon Road, Tsimshatsui, Hong Kong SAR, China 3. Department of Surgery, Pamela Youde Nethersole Eastern Hospital, Hong Kong SAR, China 4. Department of Surgery, Queen Elizabeth Hospital, Hong Kong SAR, China |
|
|
Abstract Hemoperitoneum is a rare and potentially life-threatening complication of GIST. We reported a 54-year-old man who developed disseminated intra-abdominal recurrence from a previously resected gastrointestinal stromal tumour (GIST) of the small bowel, and the patient presented with hemoperitoneum. Emergent debulking surgery was performed. A high dose imatinib was prescribed. Despite the presence of residual disease, the patient was well clinically 8 months after the operation. Even though, there is no evidence to support the routine use of debulking surgery in the management of GIST. In our patient, disease progression after second line targeted therapy and the absence of alternative treatment options for spontaneous rupture and hemoperitoneum prompted us to treat the patient aggressively. Resection of the ruptured GIST was carried out for control of bleeding and to prevent recurrent bleeding in this patient with good surgical risks. During the treatment decision-making, the patient’s general condition, the risk of surgery and the extent of dissemination were taken into consideration. In this patient who presented with spontaneous rupture of a small intestinal GIST, the novel use of targeted therapy and aggressive surgical treatment produced reasonably good survival outcome.
|
Keywords
gastrointestinal stromal tumour
hemoperitoneum
small bowel GIST
small bowel neoplasm
imatinib
|
Corresponding Author(s):
Wan Yee Lau
|
Online First Date: 04 July 2014
Issue Date: 02 March 2015
|
|
1 |
Lai EC, Lau SH, Lau WY. Current management of gastrointestinal stromal tumors—a comprehensive review. Int J Surg 2012; 10(7): 334–340
https://doi.org/10.1016/j.ijsu.2012.05.007
pmid: 22633986
|
2 |
Sorour MA, Kassem MI, Ghazal AH, El-Riwini MT, Abu Nasr A. Gastrointestinal stromal tumors (GIST) related emergencies. Int J Surg 2014; 12(4): 269–280
https://doi.org/10.1016/j.ijsu.2014.02.004
pmid: 24530605
|
3 |
Marano L, Antonio Arru GM, Piras M, Gemini S. Surgical management of acutely presenting gastrointestinal stromal tumors of the stomach among elderly: Experience of an emergency surgery department. Int J Surg. 2014 May 22. [Epub ahead of print] doi: 10.1016/j.ijsu.2014.05.025
pmid: 24859399
|
4 |
Hirasaki S, Fujita K, Matsubara M, Kanzaki H, Yamane H, Okuda M, Suzuki S, Shirakawa A, Saeki H. A ruptured large extraluminal ileal gastrointestinal stromal tumor causing hemoperitoneum. World J Gastroenterol 2008; 14(18): 2928–2931
https://doi.org/10.3748/wjg.14.2928
pmid: 18473425
|
5 |
Mahmoud A, Fadhel F, Amin M, Wael R, Amin D, Haykel B, Faouzi C, Rachid K, Mohamed J, Montasser K, Zoubeir BS. A ruptured ileal GI stromal tumor causing hemoperitoneum. Gastrointest Endosc 2010; 71(1): 185–186, discussion 186
https://doi.org/10.1016/j.gie.2009.08.022
pmid: 19879571
|
6 |
Pantaleo MA, Di Battista M, Catena F, Astorino M, Saponara M, Di Scioscio V, Santini D, Piazzi G, Castellucci P, Brandi G, Biasco G. Surgical debulking of gastrointestinal stromal tumors: is it a reasonable option after second-line treatment with sunitinib? J Cancer Res Clin Oncol 2008; 134(5): 625–630
https://doi.org/10.1007/s00432-007-0347-1
pmid: 18202855
|
7 |
Tielen R, Verhoef C, van Coevorden F, Gelderblom H, Sleijfer S, Hartgrink HH, Bonenkamp JJ, van der Graaf WT, de Wilt JH. Surgical treatment of locally advanced, non-metastatic, gastrointestinal stromal tumours after treatment with imatinib. Eur J Surg Oncol 2013; 39(2): 150–155
https://doi.org/10.1016/j.ejso.2012.09.004
pmid: 23084087
|
8 |
Bauer S, Rutkowski P, Hohenberger P, Miceli R, Fumagalli E, Siedlecki JA, Nguyen BP, Kerst M, Fiore M, Nyckowski P, Hoiczyk M, Cats A, Casali PG, Treckmann J, van Coevorden F, Gronchi A. Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib — analysis of prognostic factors (EORTC-STBSG collaborative study). Eur J Surg Oncol 2014; 40(4): 412–419
https://doi.org/10.1016/j.ejso.2013.12.020
pmid: 24491288
|
9 |
Pantaleo MA, Di Battista M, Catena F, Astorino M, Saponara M, Di Scioscio V, Santini D, Piazzi G, Castellucci P, Brandi G, Biasco G. Surgical debulking of gastrointestinal stromal tumors: is it a reasonable option after second-line treatment with sunitinib? J Cancer Res Clin Oncol 2008; 134(5): 625–630
https://doi.org/10.1007/s00432-007-0347-1
pmid: 18202855
|
10 |
Ruka W, Rutkowski P, Szaw?owski A, Nowecki Z, Debiec-Rychter M, Grzesiakowska U, Dziewirski W, Siedlecki JA, Michej W. Surgical resection of residual disease in initially inoperable imatinib-resistant/intolerant gastrointestinal stromal tumor treated with sunitinib. Eur J Surg Oncol 2009; 35(1): 87–91
https://doi.org/10.1016/j.ejso.2008.01.003
pmid: 18289826
|
11 |
Mullady DK, Tan BR. A multidisciplinary approach to the diagnosis and treatment of gastrointestinal stromal tumor. J Clin Gastroenterol 2013; 47(7): 578–585
https://doi.org/10.1097/MCG.0b013e3182936c87
pmid: 23751846
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|